Targeting the Immune System in MDS (featuring Prof Dominik Wolf)

Episode 140 • 18th April 2025 • EHA Unplugged • European Hematology Association

00:00:00 00:24:13

Share Episode

Start at

Embed

Share to X Share to Facebook Share to LinkedIn

Shownotes

Join us for a conversation between prof. Kirsten Gronbaek and her guest prof. Dominik Wolf, as they discuss targeting the immune system in MDS management. In light of accumulating evidence that inflammatory signals play a role throughout disease evolution in MDS patients, prof. Wolf elucidates the current insights and possible future therapeutic options.

He uses the example of targeting NLRP3/IL-1 axis in low-risk MDS to highlight the need of understanding the underlying cellular biology to translate that knowledge into clinical approaches. He also discusses the concept of possibly targeting both non-clonal and clonal compartments for better patient outcomes in the future.

Tune in, to hear about other future directions in treatment of MDS, such as recent developments in CAR T-cell approaches and about the central role that allo-transplantation is likely to keep in the treatment of high-risk MDS. You will also hear about the potential link between inflammation and fatigue, which is clinically highly relevant, but as yet an unsolved issue in MDS.

Host: prof. Kirsten Gronbaek

Guest: prof. Dominik Wolf